Attenuation of Pain in Men and Women
The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2010 by University of Wisconsin, Madison.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
University of Wisconsin, Madison
Information provided by:
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT01220414
First received: September 28, 2010
Last updated: October 15, 2010
Last verified: October 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to examine opioid and endocannabinoid mechanisms of exercise-induced analgesia in men and women.
| Condition | Intervention |
|---|---|
|
Pain |
Drug: Naltrexone, Drug: Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Basic Science |
| Official Title: | Attenuation of Pain in Men and Women: Mechanisms of Exercise-Induced Analgesia |
Resource links provided by NLM:
Further study details as provided by University of Wisconsin, Madison:
Primary Outcome Measures:
- Pain threshold, pain ratings, and temporal summation [ Time Frame: Before and immediately following the two experimental sessions ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 60 |
| Study Start Date: | September 2010 |
| Estimated Primary Completion Date: | January 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Men |
Drug: Naltrexone,
50 mg of naltrexone
Drug: Placebo
sugar pill
|
| Active Comparator: Women |
Drug: Naltrexone,
50 mg of naltrexone
Drug: Placebo
sugar pill
|
Eligibility| Ages Eligible for Study: | 18 Years to 40 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria: Healthy men and women
-
Exclusion Criteria:
- current cardiac or other chronic diseases (e.g., cancer, diabetes, hypertension, kidney disease); routine use of prescriptive medications; history of vasovagal response to phlebotomy; an allergy to naltrexone; pregnancy; current smokers; current use of recreational drugs; history of substance abuse
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01220414
Contacts
| Contact: Kelli F Koltyn, PhD | 608-262-4234 | Koltyn@education.wisc.edu |
Locations
| United States, Wisconsin | |
| University of Wisconsin-Madison | Recruiting |
| Madison, Wisconsin, United States, 52706 | |
| Contact: Kelli F Koltyn, Ph.D. 608-262-4234 Koltyn@education.wisc.edu | |
| Principal Investigator: Kelli F Koltyn, Ph.D. | |
Sponsors and Collaborators
University of Wisconsin, Madison
More Information
No publications provided
| Responsible Party: | Kelli F. Koltyn, University of Wisconsin |
| ClinicalTrials.gov Identifier: | NCT01220414 History of Changes |
| Other Study ID Numbers: | H-2010-0087 |
| Study First Received: | September 28, 2010 |
| Last Updated: | October 15, 2010 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Naltrexone Narcotic Antagonists Physiological Effects of Drugs Pharmacologic Actions |
Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013